Takeda CEO Admits Missteps In Expanding Global Generics Markets
This article was originally published in PharmAsia News
Takeda Pharmaceutical CEO Yasuchika Hasegawa acknowledged in an interview his company made some serious errors recently in its struggle to morph from a drug innovator to one globally competitive in generics.
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.